Skip To Main Content
Jonathan Barratt on Muck Rack

Jonathan Barratt

As seen in: Nature, Oxford Academic, MDPI, The BMJ, JAMA (The Journal of the American Medical Association), The New England Journal of Medicine, The Lancet, Canadian Medical Association Journal, Dove Medical Press, Nephrology News & Issues and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan

Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ORIGIN 3 Plenary Highlights: Atacicept Shows Remarkable IgAN Results

|
By Jonathan Barratt, Joel Topf, Anna Gaddy
| Doc Wire News Verified
At the 2026 American Society of Nephrology (ASN) Kidney Week, Joel Topf, MD, Henry Ford Health, speaks with Jonathan Barratt, MD, University of Leicester, after his plenary session presentation on the ORIGIN 3 trial, discussing final data showing that atacicept significantly slowed kidney function decline in high-risk IgA nephropathy and restored rates of kidney function loss to levels comparable with those seen in healthy individuals.
Open in Who Shared Issue with article?

Jonathan Barratt, MBChB, PhD

|
By Jonathan Barratt, Joel Topf
| Doc Wire News Verified
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Formedics, its employees, and affiliates.
Open in Who Shared Issue with article?

Atacicept-vymj meets all 2-year prespecified endpoints for adults with IgA nephropathy

|
By Lucas Laboy, Richard Smith, Jonathan Barratt
| Citeline Verified
Key takeaways: No patients in the atacicept-vymj group required dialysis or transplantation or died. The data will be submitted for full FDA approval. DENVER — Atacicept-vymj stabilized eGFR, reduced risks for a composite kidney disease progression outcome and was well tolerated vs. placebo for adults with immunoglobulin A nephropathy, according to findings presented at ASN Kidney Week.
Open in Who Shared Issue with article?
See all 94 licensed articles (194 Total)